DNMT1 and acute myeloid leukemia: Critically, our study reveals for the first time the capacity of DAC in upfront combination with chemotherapy to reduce the stemness properties of hAML relapses, further encouraging the clinical assessment of upfront combination of low-dose DNMT inhibitors with standard chemotherapy as first line treatment of AML.